Latest Headlines

Latest Headlines

China's Kelun Pharma opens $50M Kazakhstan plant for intravenous oncology drugs

China's Kelun Pharmaceutical has just opened a $50 million production plant in Almaty (formerly Alma-Ata), just across the border in Kazakhstan. Kelun Kazpharm executives told China's state-run Xinhua news agency the plant is responsible for 70% of the Kazakhstan market for intravenous medicines.

China's ZAI Lab in oncology license deal for HM61713 with South Korea's Hanmi

Shanghai-based ZAI Lab has in-licensed China rights for HM61713, a tumor-targeting EGFR tyrosine kinase inhibitor from South Korea's Hanmi, which has racked up an impressive string of license deals this year.

China healthcare reforms in gear, but not fast enough for some

China is moving on several fronts to make it easier and safer for potential patients to use the nation's expanding healthcare system, with a new emphasis on drug regulations, devices and elderly care. Even so, American drugmakers say the government should do even more in the drugs area.

New bug in China overcomes last-resort antibiotic

China is harboring what could be a doomsday bug, according to scientists who issued an alert for a possible worldwide pandemic, according to reports by  CBC News  and  Channel News Asia. The scare is even more serious because the resistant bacterium has been found in both animals and humans.

BMS gets a leg up in the China hep C race with PhI for Daklinza

China has moved closer to approval of the nation's first state-of-the-art treatment for hepatitis C, according to researchers who presented data from their initial trial at the Liver Meeting conference in San Francisco.

Pharma faces 'challenging and prolonged' reforms in China, with pricing power at risk

Big Pharma has already seen sales in China slow, thanks in part to stepped-up competition from local drugmakers. Healthcare reform there is also taking its toll. But Fitch Ratings says pharma's troubles in China are only beginning.

Indonesia's Kalbe and South Korea's Genexine link up for biomedical work

Indonesia's Kalbe Farma has signed a deal with South Korea's Genexine in which it will invest $9.1 million to develop biopharmaceutical products and create an R&D laboratory in Indonesia to research the hormone erythropoietin, which helps produce red blood cells, according to a report by the Nikkei Asian Review.

HK-based Chi-Med takes another regulatory step to Nasdaq listing

Hong Kong-based Hutchison China MediTech, or Chi-Med, has moved another notch up the U.S. listing regulatory process, filing an F-1 form with the U.S. SEC and providing a detailed financial snapshot, the company said in a press release.

British genomics project signs WuXi NextCODE as Chinese partner

Genomics England, the company set up by the country's Department of Health to sequence 100,000 human genomes, has brought in China's WuXi NextCODE as the first of its "clinical interpretation partners," according to a report by state-owned news agency Xinhua.

China FDA seeks comments on device, drug approval backlog plans

China FDA has opened a window until Dec. 13 for comments on its plans to whittle down a massive backlog on drug and medical device approval applications.